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original article

Economic Burden of Ventilator-Associated Pneumonia
Based on Total Resource Utilization
Marcos I. Restrepo, MD, MSc; Antonio Anzueto, MD; Alejandro C. Arroliga, MD; Bekele Afessa, MD;
Mark J. Atkinson, PhD; Ngoc J. Ho, PhD; Regina Schinner, Dipl-Stat; Ronald L. Bracken; Marin H. Kollef, MD

objectives. To characterize the current economic burden of ventilator-associated pneumonia (VAP) and to determine which services
increase the cost of VAP in North American hospitals.
design and setting. We performed a retrospective, matched cohort analysis of mechanically ventilated patients enrolled in the North
American Silver-Coated Endotracheal Tube (NASCENT) study, a prospective, randomized study conducted from 2002 to 2006 in 54 medical
centers, including 45 teaching institutions (83.3%).
methods. Case patients with microbiologically confirmed VAP (n p 30 ) were identified from 542 study participants with claims data
and were matched by use of a primary diagnostic code, and subsequently by the Acute Physiology and Chronic Health Evaluation II score,
to control patients without VAP (n p 90). Costs were estimated by applying hospital-specific cost-to-charge ratios based on all-payer
inpatient costs associated with VAP diagnosis-related groups.
results. Median total charges per patient were $198,200 for case patients and $96,540 for matched control patients (P ! .001 ); corresponding median hospital costs were $76,730 for case patients and $41,250 for control patients (P p .001 ). After adjusting for diagnosisrelated group payments, median losses to hospitals were $32,140 for case patients and $19,360 for control patients (P p .151 ). The median
duration of intubation was longer for case patients than for control patients (10.1 days vs 4.7 days; P ! .001 ), as were the median duration
of intensive care unit stay (18.5 days vs 8.0 days; P ! .001) and the median duration of hospitalization (26.5 days vs 14.0 days; P ! .001).
Examples of services likely to be directly related to VAP and having higher median costs for case patients were hospital care (P ! .05) and
respiratory therapy (P ! .05).
conclusions. VAP was associated with increased hospital costs, longer duration of hospital stay, and a higher number of hospital
services being affected, which underscores the need for bundled measures to prevent VAP.
trial registration.

NASCENT study ClinicalTrials.gov Identifier: NCT00148642.
Infect Control Hosp Epidemiol 2010; 31(5):509-515

The cost of hospitalization has increased by 55% during the
past decade. The most important driver of this increase was
the greater intensity of services provided during hospitalization.1 In the intensive care unit (ICU), where costs are
nearly 3 times those in the general ward,2 mechanical ventilation is an important determinant of excess costs.3 Ventilator-associated pneumonia (VAP) increases length of stay in
the ICU and in the hospital, further increasing costs.4-7 Reimbursement for cases of VAP paid to hospitals by the Centers
for Medicare and Medicaid Services (CMS) has changed over
time. Before 1983, the CMS reimbursed hospitals for many
extra costs associated with VAP on a fee-for-service basis. In

1983, Medicare implemented the prospective payment system
and reimbursed hospitals a fixed amount determined by the
principal diagnosis on hospital admission. Accordingly, patients are classified into 1 of approximately 500 diagnosisrelated groups (DRGs) that are expected to utilize similar
hospital resources; patients are classified into a DRG on the
basis of International Classification of Diseases diagnosis, procedure, age, sex, discharge status, and presence of complications or comorbidities. With this change, the costs of VAP
incurred by hospitals began to exceed Medicare reimbursement.8 This has future implications, because the incidence of
VAP will increase as a result of the aging population, and
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quality-of-care initiatives may begin to classify VAP as a preventable complication that is not reimbursable by the CMS.9
Estimates of the economic burden of VAP are quite variable
and ranged from approximately $10,0004-6 to $40,0007 per
patient episode in studies published in the early 2000s. Part
of the variability depends on whether the perspective is that
of the hospital or patient; costs incurred by hospitals4-6 are
lower than charges billed to patients.7 Variability is also attributable to differences in study design and methods, year(s)
when data were collected, hospital location(s), and many
other factors. On the basis of a literature review in which
previously published estimates were converted to 2005 US
dollars, Anderson et al10 recently estimated that the weightadjusted mean cost per episode of VAP was $25,000. Data
are limited, however, regarding the impact of VAP on different
hospital services for patients with VAP.
To characterize the current economic burden of VAP on
hospitals and to determine which services increase its cost,
we performed a retrospective cohort analysis of patients enrolled in the North American Silver-Coated Endotracheal
Tube (NASCENT) study.11 The NASCENT study was a prospective, randomized study conducted from 2002 to 2006 in
54 medical centers in North America that included 45 teaching institutions (83.3%). Adults requiring mechanical ventilation were randomly assigned to undergo intubation with
a silver-coated tube (Agento I.C.; Bard) or an uncoated tube
(Hi-Lo Endotracheal Tube; Mallinckrodt). Of the 1,509 patients who were intubated for 24 hours or longer, 93 (6.2%)
developed microbiologically confirmed VAP (ie, 37 [4.8%] of
766 patients using the silver-coated tube and 56 [7.5%] of
743 patients using the uncoated tube [P p .03]). The preliminary results of this cohort analysis of the NASCENT study
have been reported elsewhere.12

methods
To characterize the economic burden of VAP on hospitals
and to determine which services increase its cost, we performed a retrospective matched cohort analysis of patients
enrolled in the NASCENT study.11 Each medical center’s institutional review board approved the NASCENT study. Written informed consent was required and obtained from patients or their legally authorized representatives.
Patients with medical insurance claim forms and International Classification of Diseases, Ninth Revision, Clinical Modification procedural codes for mechanical ventilation (codes
96.70–96.72 for mechanical ventilation or codes 96.01–96.05
for nonsurgical intubation of the respiratory tract) were eligible
for inclusion in our retrospective cohort analysis. The diagnosis
of VAP was based on the presence of 104 colony-forming units
or more per milliliter of a pathogen in quantitative bronchoalveolar lavage fluid obtained from patients intubated for
24 hours or longer. Standard diagnostic criteria13,14 were used
for determining when to obtain samples for culture, namely,
suspicion of VAP or the presence of a new radiographic infil-

trate, plus 2 of the following 3 qualifying clinical signs: fever
or hypothermia, leukocytosis or leukopenia, and/or purulent
tracheal aspirate. Case patients were defined as patients with
microbiologically confirmed VAP; control patients were defined
as patients without microbiologically confirmed VAP. Each case
patient was matched to as many control patients as possible
by primary diagnostic code at admission, receipt of mechanical
ventilation services, and microbiological evidence and was subsequently matched by Acute Physiology and Chronic Health
Evaluation (APACHE) II score at ICU admission.
The primary economic outcome was hospital cost, which
was computed for each patient by linking charge data to a
source of accounting data with the ratio of hospital cost to
patient charge (hereafter the cost-to-charge ratio) for each
hospital and multiplying the hospital-specific cost-to-charge
ratio by the charges for each case. The cost-to-charge ratios
were obtained from CMS historical impact files for the fiscal
years 2003–2005, with the appropriate annual impact file determined by patient discharge date.
Medicare reimbursement was based on DRG payments and
computed for each patient according to the following formula: [(standardized labor share # operating wage index) ⫹
(standardized nonlabor share # operating COLA adjustment
for hospitals)] # (1 ⫹ operating IME ⫹ operating DSH adjustment factor) # (DRG weight)].15 Standardized labor-related and nonlabor-related amounts were based on the Federal Register rules and regulations files for each year. Data
on the operating wage index, the cost-of-living adjustment
(COLA), the indirect medical education (IME) payment, and
the disproportionate share hospital (DSH) adjustment were
obtained from CMS historical impact files for the fiscal years
2003–200516 and were used to adjust payment impacts of
policy changes to DRG payments. A hospital that qualifies
for the DSH adjustment receives higher Medicaid reimbursement than do other hospitals because it treats a disproportionate share of Medicaid patients. The difference in the number of nonzero charge events was computed by adding the
number of nonzero charge events within each CMS revenue
category for each patient, which allows for between-group
comparison of the number of events occurring in each service
unit.
Patients’ characteristics and their risk factors for VAP within 30 days of hospital admission were compared between
groups at baseline. Median hospital charges were calculated
for each service category. Costs were estimated by applying
hospital-specific cost-to-charge ratios based on all-payer inpatient costs. The median duration of intubation and the
median duration of length of stay were calculated for each
cohort. Between-group differences were analyzed by use of
the Wilcoxon-Mann-Whitney test and 1-way analysis of variance for continuous variables and by use of the x2 test for
categorical variables. A P value of less than .05 was considered
to be statistically significant. SAS (SAS Institute) and Stata
(StataCorp) were used for statistical analysis.

economic burden of vap
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results
Of the 2,003 patients enrolled in the NASCENT study, 524
(26.2%) had medical insurance claims data.11 Of these 524
patients, 30 (5.7%) had microbiologically confirmed VAP and
were matched by diagnostic code to 90 control patients without VAP (Figure 1). There were no statistically significant differences between cohorts in demographic characteristics at
baseline or in risk factors for VAP within 30 days of admission
(Table 1).
Median total hospital charges were $198,200 for case patients with VAP and $96,540 for control patients without VAP
(P ! .001) (Table 2). The average derived cost-to-charge ratios
were similar for case patients and control patients (0.38 vs
0.41; P p .203), resulting in median costs of $76,730 for case
patients and $41,250 for control patients (P p .001). After
adjusting for DRG payments, median losses to hospitals were
$32,140 for case patients and $19,360 for control patients
(P p .151). Between-cohort differences remained statistically
significant in the subset of patients who survived, except for
median losses to hospitals (P p .054).
Services with the highest median costs for case patients and
control patients were hospital services ($23,190 vs $11,110;
P p .004), pharmacy services ($10,990 vs $6,310; P p .101),
laboratory services ($8,512 vs $6,102; P p .271), and respiratory therapy ($4,838 vs $2,787; P p .018) (Table 3). Additional services with higher median costs for case patients
than for control patients included cardiology services (P p
.046), operating room services (P ! .001), electrocardiogram
services (P p .017), nuclear medicine services (P p .042),
and recovery room services (P p .030).
The duration of intubation, the duration of ICU stay, and
the duration of hospitalization were longer for case patients
with VAP than they were for control patients without VAP
(Table 4). Between-cohort differences remained statistically
significant in the subset of patients who survived.

discussion
Our study examined the costs associated with patients with
VAP diagnosed on the basis of microbiologic criteria, thereby
avoiding the limitations of clinically diagnosed VAP and helping to delineate excess costs associated with this diagnosis.
Unlike economic studies that focus on major cost determinants, such as length of stay, our approach provides a comprehensive analysis of the many different services that contribute to the economic burden of VAP. In addition, our
approach includes both costs based on the cost-to-charge
ratio and Medicare payments based on DRG, allowing calculation of the loss to hospitals for patients with VAP. Most
economic outcomes, including charges, costs, and DRG payments, were significantly higher for case patients with VAP
than for control patients without VAP. For example, the median total hospital cost was $35,480 higher for case patients
with VAP than for control patients without VAP. The total
hospital cost was higher for case patients with VAP because

figure 1. Flowchart summarizing enrollment of participants from
the North American Silver-Coated Endotracheal Tube (NASCENT)
study into the present study. APACHE, Acute Physiology and Chronic
Health Evaluation; VAP, ventilator-associated pneumonia.

of the increased utilization of services, such as those provided
by the hospital, respiratory department, and other patientservice units that may contribute indirectly. In addition, the
duration of intubation, the duration of ICU stay, and the
duration of hospitalization were longer for case patients with
VAP than for control patients without VAP.
Other studies4-7 have also reported that costs were significantly increased among case patients with VAP, compared
with control patients without VAP. The highest estimate of approximately $40,000 was based on mean charges of $100,000
for case patients and $60,000 for control patients in a retrospective, matched cohort study of patients hospitalized in
the late 1990s.7 As expected, estimates of costs were lower
than those of charges. For example, mean attributable costs
from the same time period were approximately $10,000 in a
retrospective, matched cohort study4 and $12,000 in a prospective surveillance of patients with costs estimated by use
of a step-down allocation method with multiple linear regression modeling to adjust costs for significant variables.6
Safdar et al5 estimated that the additional costs were approximately $10,000 on the basis of a quantitative systematic
literature review of studies published from 1991 to 2003 and
on the basis of microcosting that used attributable length of
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table 1. Data on Case Patients with Ventilator-Associated Pneumonia (VAP) and Control Patients without
VAP from the North American Silver-Coated Endotracheal Tube Study, 2002–2006
Case patients
(n p 30)

Characteristic
Male sex
Age
Median Ⳳ SD, years
Range, years
APACHE II score, median (range)
Risk factors for VAP within 30 days of hospitalization
Functional dependency
Smoking
Impaired sensorium
COPD
Long-term steroid use
Emergency surgery or trauma
None
Immunodeficiencya
Use of silver-coated endotracheal tube
Duration of intubationb
Median (range), days
X4 days
14 days
Mortality

Control patients
(n p 90)

18 (60.0)

43 (47.8)

68.0 Ⳳ 15.6
32–87
18.0 (11–40)

64.5 Ⳳ 17.6
24–98
18.0 (9–40)

7
1
6
3
2
1
3
4
16

(23.3)
(3.3)
(20.0)
(10.0)
(6.7)
(3.3)
(10.0)
(13.3)
(53.3)

11
15
11
9
9
11
18
26
45

(12.2)
(16.7)
(12.2)
(10.0)
(10.0)
(12.2)
(20.0)
(28.9)
(50.0)

3.7
16
14
5

(1.0–11.4)
(53.3)
(46.7)
(16.7)

4.7
36
54
29

(1–21.8)
(40.0)
(60.0)
(32.2)

P
.246
.413

.925
.140
.063
.290
1.99
.584
.160
.212
.088
.752
.332
.202c
.102

note. Data are no. (%) of patients, unless otherwise indicated. APACHE, Acute Physiology and Chronic Health Evaluation;
COPD, chronic obstructive pulmonary disease; SD, standard deviation.
a
Defined as 12 weeks of high-dose steroids, presence of human immunodeficiency virus antibody, chemotherapy within 45
days, chemotherapy-induced neutropenia, or immunosuppression for organ transplantation.
b
For case patients, we determined the duration of intubation before the onset of VAP.
c
Determined from x2 analysis of case patients and control patients for group values.

stay data. More recently, Anderson et al10 estimated that the
weight-adjusted mean costs were $25,000 per episode of VAP
on the basis of a literature review, with costs standardized to
US dollars in 2005. Collectively, findings from previous studies combined with our findings suggest that the economic
burden of VAP incurred by hospitals is increasing.
Our study updates the body of evidence used to charac-

terize the economic burden of VAP and to determine which
services increase cost; this body of evidence is essential because CMS reimbursement is based on DRGs, not on each
of the services utilized. In addition, our study provides data
to incentivize the use of preventive strategies in North American hospitals, which will become more important if the CMS
classifies VAP as a nonreimbursable, preventable complica-

table 2. Total Hospital Charges and Costs for Case Patients with Ventilator-Associated Pneumonia (VAP) and Control
Patients without VAP from the North American Silver-Coated Endotracheal Tube Study, 2002–2006
Case patients
(n p 30)

Type of patients, charges and costs
All patients
Charges, US$
CCR costs, US$
Average derived CCR
DRG payment, US$
CCR cost minus DRG payment, US$
Survivorsa
Charges, US$
CCR costs, US$
Average derived CCR
DRG payment, US$
CCR cost minus DRG payment, US$
note.
a

Control patients
(n p 90)

P

198,200
76,730
0.38
39,840
32,140

(46,480–579,700)
(9,713–276,500)
(0.18–0.54)
(7,151–152,400)
(⫺34,330 to 191,600)

96,540
41,250
0.41
17,840
19,360

(28,920–531,800)
(8,247–171,600)
(0.18–0.62)
(4,374–126,200)
(⫺84,860 to 126,300)

!.001

202,500
89,550
0.38
40,370
36,920

(88,180–579,700)
(33,860–276,500)
(0.19–0.54)
(30,000–152,400)
(⫺10,590 to 191,600)

102,300
43,020
0.40
20,510
25,300

(31,030–531,800)
(8,247–171,600)
(0.18–0.62)
(4,374–109,400)
(⫺67,490 to 114,000)

!.001
!.001

Data are median values (range). CCR, (hospital) cost–to–(patient) charge ratio; DRG, diagnosis-related group.
There were 25 case patients and 61 control patients who survived.

.001
.203
.001
.151

.683
.004
.054
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table 3. Hospital Costs for Case Patients with Ventilator-Associated Pneumonia (VAP) and Control
Patients without VAP from the North American Silver-Coated Endotracheal Tube Study, 2002–2006, by
Selected Types of Service
Median cost (range), US$
Service (CMS codes)
Hospital (110–214)
Pharmacy (250–259)
Laboratory (300–309)
Respiratory therapy (410–419)
Radiology (320–333)
Cardiology (480–489)
Computed tomography (350–359)
Operating room (369–371)
Blood (380–391)
Electrocardiogram (730–740)
Pulmonary diagnostic, unlisted (460)
Orthopedic diagnostic (920–924)
Occupational therapy (430–434)
Orthopedic rehabilitation (940–949)
Renal (800–809, 881)
Ambulatory (490)
Nuclear medicine (340–343)
Recovery room (710–719)
note.

Case patients
(n p 30)
23,190
10,990
8,512
4,838
1,531
968
737
717
512
291
196
145
17
0
0
0
0
0

(2,079–76,070)
(1,376–70,580)
(1,541–43,340)
(0–20,070)
(287–5,426)
(0–14,040)
(0–9,300)
(0–1,515)
(0–33,430)
(0–2,016)
(0–10,770)
(0–3,177)
(0–2,021)
(0–8,023)
(0–5,165)
(0–4,479)
(0–1,557)
(0–1,060)

Control patients
(n p 90)
11,110
6310
6,102
2,787
1,179
491
818
0
385
126
0
0
0
0
0
0
0
0

P

(661–90,330)
(306–47,220)
(935–29,500)
(0–17,500)
(188–8,760)
(0–6,029)
(0–5,644)
(0–1,882)
(0–37,620)
(0–2,571)
(0–5,994)
(0–1,900)
(0–852)
(0–1,199)
(0–5,707)
(0–1,364)
(0–1,131)
(0–1,173)

.004
.101
.271
.018
0.146
0.046
.167
!.001
.544
.017
.108
.134
.067
.210
.668
.379
.042
.030

CMS, Centers for Medicare and Medicaid Services.

tion. Preventive strategies13,17,18 are often bundled, but implementation is challenging. Educational interventions have
been shown to be successful at encouraging the use of bundled preventive strategies, and the use of these interventions
has been shown to significantly reduce infection rates in prospective observational studies.19-21 Unfortunately, these benefits tend to subside when there is a lack of continuous educational reinforcement, and nonadherence is common among
clinicians.22-24 Barriers to adherence include a lack of resources
and an increase in costs.22,24 To maximize the likelihood of success, Craven25 advocates a team approach comprising infection
control professionals, infectious disease specialists, critical care
nurses and physicians, respiratory care staff, administrators,
risk management staff, microbiologists, and other stakeholders—all under the direction of an advocate or “champion”
who can market preventive strategies to decision makers responsible for allocating resources. Our findings provide economic support for this multidisciplinary approach, and the
diversity of services impacted by VAP suggests that the list of
team members and services may need to be expanded.
Our study had several limitations, some of which are inherent to retrospective cohort analyses. First, our findings were
subject to selection bias due to the retrospective design, but
data were obtained from a large, prospective, multicenter, randomized study.11 To limit bias, we matched case patients to
control patients by primary diagnostic code and APACHE II
score; on the basis of baseline demographic characteristics of
patients and their risk factors for VAP, the cohorts appeared
to be balanced (ie, all P values greater than .05). Our findings

were also subject to selection bias inherent to a randomized,
controlled study performed primarily at teaching hospitals in
the United States, and therefore they may not be generalizable
to nonteaching hospitals or to other countries. In addition, we
table 4. Duration of Intubation and Length of Stay (LOS) for
Case Patients with Ventilator-Associated Pneumonia (VAP) and
Control Patients without VAP from the North American SilverCoated Endotracheal Tube Study, 2002–2006
Median no.
of days (range)
Type of patient
and variable
All patients
Intubation durationa
VAP onset X4 days
VAP onset 14 days
Intensive care unit LOSa
VAP onset X4 days
VAP onset 14 days
Hospital LOSa
VAP onset X4 days
VAP onset 14 days
Survivorsb
Intubation duration
Intensive care unit LOS
Hospital LOS
a
b

Case
patients
(n p 30)
10.1
9.1
12.9
18.5
11.5
23.5
26.5
18.5
31.5

Control
patients
(n p 90)

P

(3–25)
4.7 (1–22)
(3–20)
(5–25)
(5–33)
8.0 (2–33)
(5–29)
(6–33)
(5–36) 14.0 (3–50)
(5–31)
(20–36)

!.001

10.2 (3–25)
4.8 (1–22)
19.0 (5–33)
8.0 (2–33)
29.0 (12–36) 16.0 (3–50)

!.001
!.001
!.001

!.001

!.001

Duration after VAP onset.
There were 25 case patients and 61 control patients who survived.
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focused on microbiologically documented VAP, as described in
the NASCENT study11; other studies4-7 have reported the economic burden of clinically suspected VAP, with and without
microbiologic confirmation, as aggregate findings.
Second, claims data were available for only one-fourth of
patients in the NASCENT study,11 but the 30 case patients
represent the largest economic study of patients with microbiologically confirmed VAP. Third, the two-fold increase in
mortality among control patients was unexpected and could
have contributed to between-cohort differences in cost and
length of stay; however, between-cohort differences remained
statistically significant among survivors. Fourth, microcosting
was not feasible for this large multicenter study, so costs were
estimated by summing charges from individual services and
then applying the estimated cost-to-charge ratios on the basis
of matched CMS DRGs. We were not able to obtain servicespecific ratios or patient-specific actual costs but did use hospital-specific ratios and charges for each hospital. Fifth, sample size precluded statistical evaluation of the onset of VAP
on economic burden, but the higher cost of late-onset, as
opposed to early-onset, VAP has already been reported.6 Sixth,
we performed an unmatched statistical analysis on matched
data, which would tend to increase estimates of standard error and make it more difficult to detect between-group differences. An unmatched approach almost certainly resulted in
a conservative analysis of between-group differences. Seventh,
an estimation of attributable costs, including each of the services shown in Table 3, was not feasible, but other studies
have shown that patients with VAP have higher attributable
costs than do patients without VAP.4-6
In conclusion, case patients with microbiologically confirmed VAP had a longer duration of mechanical ventilation,
a longer ICU stay, and a longer hospital stay than did control patients without VAP, which led to significantly higher
charges, hospital costs, and DRG payments. Our findings add
to the current body of literature regarding the economic burden of VAP and the types of services that play a role in
increasing the cost of hospital care for patients with VAP. The
increased total costs and the diversity of resources utilized
underscore the need for bundled measures to prevent VAP.
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